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Introduction
Th  e vasculitides comprise a heterogenous group of 
conditions that are currently classiﬁ  ed according to the 
size of blood vessels predominantly involved [1,2]. 
Typically, vasculitides involving predominantly small- to 
medium-size vessels are associated with multiple organ 
involvement, including a predilection for the lung, 
whereas pulmonary involvement of large vessel vascu-
litides is rarer. Th  is review therefore focuses on small 
vessel vasculitides and their pulmonary manifestations: 
pulmonary capillaritis leading to alveolar hemorrhage is 
the classic manifestation of small-vessel vasculitis and 
occurs most frequently in the context of the anti-
neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitides (AAVs). Th  e AAVs represent the most 
frequent underlying condition of alveolar hemorrhage. 
Wegener’s granulomatosis (WG), microscopic poly-
angiitis (MPA) and Churg-Strauss syndrome (CSS) share 
the features of small vessel vasculitis and a (variable) 
association with ANCAs and are therefore termed AAVs. 
Yet whereas MPA may be regarded as a ‘pure’ small- to 
medium-size vessel vasculitis, the other two AAVs (WG and 
CSS) feature more than just vasculitic manifestations. In 
WG the spectrum of organ manifestations encom  passes 
inﬂ  ammatory mass formation (‘granuloma  tous disease’), 
which is most prevalent in the upper and lower 
respiratory tracts and characterized by tumor-like inﬁ  l-
trative or destructive disease. In CSS, ‘granuloma forma-
tion’ may also be found, though less pronounced; 
furthermore, asthma, hypereosinophilia and eosinophilic 
organ inﬁ  ltration are hallmarks of CSS.
Wegener’s granulomatosis
Clinical features and histology
From the clinical point of view, WG is characterized by 
two features: mass formation and ANCA-associated 
small- to medium-size AAV. Th  e former is usually 
restricted to the upper and lower respiratory tracts and 
its characteristic histology features constitute granulo-
ma  tous and necrotizing inﬂ  ammation, yet vasculitis may 
also be found within the granulomatous inﬂ  ammation 
[2]. Th  e latter may aﬀ   ect virtually any organ, with a 
predilection for lung and kidney involvement (necro-
tizing, predominantly small-vessel pauci-immune vascu-
litis, that is, manifesting as pulmonary capillaritis and 
crescentic glomerulonephritis) [3,4]. Th   ere is some 
evidence from in vitro and in vivo studies that ANCAs 
play a crucial role in the mediation of small-vessel 
vasculitis [5-7]. In WG, ANCAs are mainly directed 
against Proteinase 3 [4] and are implicated in the activa-
tion of polymorphonuclear neutrophils by interacting 
with Proteinase 3 expressed on the plasma membrane of 
these [5].
Disease stages
According to a concept by Fienberg [8], WG starts as 
‘granulomatous’ disease of the upper and lower respira-
tory tracts and subsequently progresses to generalized 
(‘systemic’) disease characterized by clinical vasculitis 
manifestations, such as pulmonary capillaritis or necro-
tizing glomerulonephritis. Th  is concept has been incor-
porated in the European deﬁ  nition of disease stages of 
AAV introduced in 1995 [9] and has been updated several 
times since then. In the current deﬁ   nitions [10], the 
localized disease stage, deﬁ   ned as manifestations 
restricted to the respiratory tract (that is, rhinitis, 
sinusitis, pulmonary masses) with no clinical signs of 
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© 2011 BioMed Central Ltdvasculitis (no pulmonary capillaritis), is diﬀ  erentiated 
from the systemic disease stages (early systemic, general-
ized and severe disease), all of which are associated with 
clinical signs of vasculitis. In the systemic disease stages, 
patients usually present with pronounced constitutional 
symptoms (weakness, fever, weight loss). Whereas early 
systemic disease is considered non-life-threatening (that 
is, occurring with arthritis, episcleritis or purpura), 
generalized disease is deﬁ   ned as organ- or life-
threatening (that is, due to glomerulonephritis or alveolar 
hemorrhage). In severe disease, organ failure has 
occurred due to systemic vasculitis manifestations (that 
is, renal failure; Table 1). Th  e  deﬁ  nition of these disease 
and activity stages [10] has facilitated the generation of 
evidence-based, stage-adapted treatment regimens. For 
most disease stages (except for localized disease), 
evidence from controlled trials is available to guide 
treatment decisions [11].
Respiratory tract manifestations
WG usually starts with symptoms due to upper respira-
tory tract involvement: manifestations aﬀ  ecting the nasal 
and oral cavity, the sinuses and the trachea are reported 
to occur in 75 to 93% of patients at diagnosis and in up to 
99% during the course of the disease [3,4,12]. Upper 
respiratory tract involvement not only occurs early in the 
disease course, but is the most frequent manifestation of 
WG [4], and for these two reasons is indicative of WG: 
patients typically present with rhinosinusitis with bloody 
discharge, crusting and epistaxis. Nasal crusting (‘golden 
crusts’) is a typical ﬁ  nding of endoscopic evaluation.
Granulomatous inﬂ  ammation and/or mass formation 
may be found in the nasal cavity, sinuses and within the 
orbits but also frequently in the lower respiratory tract as 
pulmonary ‘granuloma’ [3,4] (Figure 1). Orbital masses, 
either perforating from the sinuses or developing within 
the orbit in isolation, are a serious complication of upper 
respiratory tract disease in 15 to 20% of patients [4]. Th  e 
nature of granulomatous inﬂ  ammation is destructive, as a 
signiﬁ   cant proportion of patients develop signs of 
cartilage and bone erosion during the course of disease 
(that is, saddle nose deformity or orbital wall destruc-
tion), as has recently been shown in a study of localized 
WG patients [13]. Trachea and bronchi may also be 
aﬀ   ected by ulcerative or granulomatous inﬂ  ammation, 
which may result in subglottic or bronchial stenosis.
Th  e overall incidence of pulmonary involvement is 
frequent (between 60% and 85%) and constitutes 
‘granulo  matous’ as well as ‘vasculitic’ manifestations 
[3,4,12]. Pulmonary nodules/masses (‘granuloma’) have 
been described on conventional radiography in around 
60% of cases [3]. Diﬀ   use alveolar hemorrhage due to 
vasculitis has been documented in 7 to 45% of patients 
[3,4] (Figure 2).
Respiratory tract manifestations of the localized disease 
stage
Th   e occurrence of ‘granulomatous’ manifestations of the 
upper and/or lower respiratory tract with no clinical 
signs of vasculitis has been deﬁ  ned as the localized stage 
(formerly the initial phase) [10], which is considered a 
transient stage before the patient develops systemic, 
clinical manifestations of vasculitis (which is present in 
all other disease stages). Yet, around 5 to 10% of patients 
remain in this disease stage and do not progress to 
systemic disease [13]. As outlined above, rhinitis, sinus-
itis, granulomatous mass formation (in sinuses, orbita 
and lung) as well as ulcerative or granulomatous and 
stenotic inﬂ  ammation of trachea and bronchi (subglottic 
and bronchus stenosis) are manifestations of the localized 
stage. Cavitating nodules or masses with a diameter of 
greater than 3 cm on high-resolution computed tomo-
graphy (HRCT) as well as parenchymal opaciﬁ  cation are 
considered active lesions [14,15]. In contrast to 
generalized disease, the localized stage has been 
presumed mild and non-organ threatening, a ﬁ  nding that 
has recently been refuted by a cohort study on localized 
WG [13]. In this study, all patients developed upper 
Table 1. Defi  nition of disease stages in antineutrophil cytoplasmic antibody-associated vasculitis according to EULAR [8]
 Systemic  Threatened    Serum
Clinical  vasculitis outside  vital organ  Other  creatinine 
subgroup  ENT and lung  function  defi  nitions  (μmol/l)  Pulmonary manifestations
Localized  No  No  No B-symptoms  <120  Ulcerative bronchitis/bronchial stenosis in WG
      ANCA typically negative    Pulmonary masses ‘granuloma’ in WG
Early systemic  Yes  No  B-symptoms  <120  As above
      ANCA negative or positive
Generalized  Yes  Yes  ANCA positive  <500  As above
          Pulmonary capillaritis, alveolitis
Severe  Yes  Organ failure  ANCA positive  >500  As above with organ failure
Refractory  Yes  Yes  Refractory to standard therapy  Any  As above, resistant to standard therapy
ANCA, antineutrophil cytoplasmic antibody; ENT, ear-nose-throat; EULAR, European League Against Rheumatism; WG, Wegener’s granulomatosis. Adapted from [11] 
with permission.
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proportion of patients developed destructive lesions 
within the upper respiratory tract: 30% saddle nose 
deformity; 28% nasal septal perforation; 18% suﬀ  ered 
from space-consuming granulomatous masses leading to 
subglottic inﬂ  ammation and stenosis; 20% had pulmo-
nary involvement with pulmonary mass formation. Due 
to resistant tumor-like mass formation and/or des-
tructive, inﬁ  ltrating inﬂ  ammation, nearly 50% required 
highly potent immunosuppression (with cyclo  phos  pha-
mide) and 66% of patients acquired some kind of organ 
damage over the whole course of follow-up.
Respiratory tract manifestations of the generalized disease 
stage
‘Granulomatous’ manifestations may persist or even 
develop throughout the generalized disease stage, yet this 
stage is, per deﬁ  nitionem, associated with organ- and or 
life-threatening vasculitis manifestations. In the lung, 
diﬀ   use alveolar hemorrhage (DAH) due to alveolar 
capillaritis is the classic manifestation of this disease 
stage. DAH has been reported to occur in 7 to 45% of 
patients and may develop in conjunction with glomerulo-
nephritis, which is summarized under the term pulmonary-
renal syndrome. Hemoptysis and dyspnea are charac-
teristic clinical signs of DAH, although a signiﬁ  cant 
proportion of patients with DAH presents without 
hemoptysis. An increase in diﬀ  using capacity of >30% is 
suggestive of DAH in patients at risk. Diﬀ  use uni- or 
bilateral alveolar shadowing on X-ray should raise the 
suspicion of DAH. HRCT scans typically show diﬀ  use 
ground glass opacities. DAH can be conﬁ  rmed by ﬁ  ber-
optic bronchoscopy, which may show diﬀ  use bleeding 
arising from the pulmonary parenchyma and/or increas-
ingly bloody lavage ﬂ  uid in consecutive portions during 
bronchoalveolar lavage. Th   e amount of alveolar 
hemorrhage may be semiquantitatively assessed by the 
number and the intensity of staining of hemosiderinladen 
alveolar macrophages (‘Golden score’). DAH may manifest 
as subclinical disease, but bleeding can also be severe and 
lead to a signiﬁ  cant fall in hematocrit, hypovolemic shock 
and respiratory insuﬃ   ciency. Mortality of DAH in AAV 
depends on severity and is estimated at 50 to 60% when 
mechanical ventilation is required [16,17].
Apart from DAH, pulmonary involvement may also be 
present in the form of alveolitis that is not associated 
with capillaritis and DAH. Alveolitis is related to diﬀ  use 
or interstitial pulmonary inﬁ   ltrates on X-ray and a 
ground-glass pattern in CT. Active disease is associated 
with an increased neutrophil count in the broncho-
alveolar lavage ﬂ  uid [18]. An elevation of CD4+ T lympho-
cytes may also be found, mainly in conjunction with an 
interstitial inﬁ  ltrate [18].
Microscopic polyangiitis
Clinical features, disease stages and histology
MPA may be regarded as ‘pure’ small- to medium-size 
vessel vasculitis that is associated with a positive ANCA 
status in more than 90% of cases, usually with perinuclear 
ANCAs (P-ANCAs) or myeloperoxidase-speciﬁ  c ANCAs 
(MPO-ANCAs). MPA has an incidence of three people 
per million per year and shows a slight male pre-
dominance [19,20] with an average onset between 50 and 
60 years of age. In contrast to WG, patients with MPA do 
not present with a classic localized stage of the disease. 
Figure 1. X-ray showing bilateral pulmonary granuloma in a 
Wegener’s granulomatosis patient.
Figure 2. Diff  use bilateral infi  ltrations on plain X-ray due to 
alveolar hemorrhage as occurring in Wegener’s granulomatosis, 
micorscopic polyangiitis and Churg-Strauss-syndrome. In 
order to verify that infi  ltrations are due to alveolar hemorrhage, 
bronchoalveolar lavage is required.
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occur [20,21], but granulomatous tumor-like or des  truc-
tive processes of the upper and lower respira  tory tract are 
lacking. At disease onset, constitutional symp  toms are 
common [19,21]. Patients may present initially with either 
a non-life-threatening course (‘early systemic disease’, 
that is, arthralgia, arthritis, episcleritis), which may 
progress to ‘generalized’ disease, or acute organ- or life-
threatening disease (‘generalized’ or ‘severe’ disease stage, 
that is, necrotizing glomerulonephritis or DAH) within 
days or weeks. Similar to WG, there is a pre  dilection for 
vasculitic manifestations of kidney (glomeru  lo  nephritis) 
and lung (alveolar capillaritis): glomeru lo nephritis  has 
been reported to occur in 80 to 100% of patients [19-22] 
and is even more frequent than in WG; and alveolar 
hemorrhage due to capillaritis has been reported in 12 to 
55% of patients [19-22] (Figure 2). In biopsy specimens, 
small- to medium-size necrotizing pauci-immune 
vasculitis is to be found with no evidence of granuloma 
formation.
Respiratory tract manifestations
DAH is the classic pulmonary manifestation in MPA and 
has been described to occur in 12 to 55% of patients 
[19-22]. MPA shows the highest frequency of DAH and/
or glomerulonephritis among the AAVs, occurring either 
as isolated organ involvement or together as pulmo-renal 
syndrome. As in WG, it has a wide spectrum, ranging 
from asymptomatic disease to a severe life-threatening 
stage.
Pulmonary ﬁ  brosis has been recognized as a pulmonary 
manifestation of MPA (Figure 3). Only few cases and a 
larger retrospective case series have been reported in the 
literature, most of which demonstrated an association of 
pulmonary ﬁ  brosis with MPO-ANCA-positive AAV or 
MPA [23-25], suggesting a pathogenic role of MPO or 
MPO antibodies in MPA-associated pulmonary ﬁ  brosis. 
Pulmonary ﬁ   brosis may develop after other clinical 
manifestations of MPA, but has also been reported to 
occur before disease onset [24], and it may have a usual 
interstitial pneumonia (UIP) or noninterstitial pneu-
monia (NSIP) pattern on HRCT and is associated with 
lower total lung capacity and increased mortality [26].
Churg-Strauss syndrome
Clinical features, disease stages and histology
CSS is characterized by peripheral blood hyper  eosino-
philia, tissue eosinophilia, asthma and vasculitis [1,2]. 
Th   e association with ANCAs is less strong; ANCAs can 
be detected in around 40% of individuals with CSS, in 
most cases P-ANCAs or MPO-ANCAs [27]. Th  ere is a 
sub  stantial clinical overlap with the hypereosinophilic 
syn  drome (HES). In fact, in some cases it might be 
diﬃ   cult to strictly diﬀ  erentiate between CSS and HES. 
According to recent classiﬁ  cation proposals, CSS may be 
seen as a subtype of HES [28]. CSS usually develops in 
three distinct phases: the ﬁ  rst phase is indistinguishable 
from poorly controlled asthma and may last for several 
years; the second phase is characterized by profound 
blood eosinophilia; and ﬁ  nally, with additional manifes-
tations of small vessel vasculitis or histological evidence 
of vasculitis, the diagnosis of CSS can be established [29]. 
In general CSS may involve any organ system, although 
the lungs (90 to 100%), the peripheral nervous system 
(approxi  mately 70%), the skin (50 to 70%) and the heart 
(approximately 50%) are predominantly aﬀ  ected [30,31]. 
According to the literature, ENT involvement is seen in 
about 50% of patients; in our own experience, sinusitis, 
polyposis or rhinitis are found in more than 90% if 
examination by an ENT specialist is part of the work-up 
(unpublished observation). Constitutional symptoms are 
common.
ANCAs are correlated with distinct clinical manifes  ta-
tions: in ANCA-positive CSS, classical vasculitis manifes-
tations, such as glomerulonephritis, pulmonary vasculitis 
with DAH or peripheral neuropathy, are more frequent, 
whereas heart-involvement is seen more often in ANCA-
negative CSS [29]. Evidence from genetic studies further 
supports the view of at least two distinct disease subtypes 
[32].
In the absence of surrogate parameters for vasculitis, 
the evaluation of biopsy specimens is crucial to diﬀ  er-
entiate between HES and CSS since the latter requires 
histological evidence of necrotizing vasculitis as long as 
no clinical surrogate such as glomerulonephritis is 
present. In the original publication by Churg and Strauss 
[33] three characteristic features were described: tissue 
Figure 3. X-ray showing pulmonary fi  brosis in microscopic 
polyangiitis.
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ma  tion. Tissue inﬁ  ltration by eosinophils is very common 
and believed to represent a major pathogenic mechanism; 
however, it is not speciﬁ   c for CSS and cannot aid 
delimitation towards HES.
Deﬁ  nitions for disease stages and activity should be 
used as suggested for AAV (Table 1), although the 
evidence for those deﬁ  nitions was derived mainly from 
studies in WG and MPA. Th   e Five Factor Score (FFS) for 
CSS was found to predict mortality and should be used as 
a prognostic tool [34,35].
Respiratory tract manifestations
Respiratory tract involvement is very common in CSS. 
Th   e vast majority of patients (>90%) suﬀ  er from bronchial 
asthma. In spite of the high frequency of asthma in CSS 
patients, clinical features of asthmatic manifestations and 
subtypes of asthma have not yet been described in detail. 
Th   ere are no reliable markers to predict the development 
of CSS in asthmatics. In the majority of patients asthma 
is characterized by adult onset and a relatively low 
prevalence of inhalational allergies. Frequently, a ten-
dency to more severe or ‘diﬃ     cult to treat’ asthma is 
observed. In more than 80% of cases asthma precedes the 
onset of vasculitis by a median time of 4 years [36]. Lung 
function testing often shows persistent airﬂ  ow obstruc-
tion in CSS patients with asthma [37]. Some reports link 
the use of a leukotriene receptor antagonist to CSS, 
although many experts believe that leukotriene receptor 
antagonists simply unmask CSS by allowing for reduction 
of systemic steroids. In a recent study, however, the 
association between leukotriene receptor antagonist and 
CSS could not be explained by steroid withdrawal in the 
majority of cases [38].
Reported frequencies of nasal polyposis, sinusitis and 
rhinitis vary and, according to our experience, are under-
estimated as long as no routine examination by an ENT 
specialist and/or cranial MRI is included in the work-up 
procedure. Upper respiratory tract manifestations in CSS 
can be distinguished from WG due to the lack of mass 
formation and destruction. Granulomatous lesions are a 
feature in biopsy specimens, yet the clinical or radio-
logical appearance of granulomatous mass formation is 
usually not seen in CSS.
Pleural eﬀ  usions can be seen in 10% of cases and might 
either be a sign of congestive heart failure due to heart 
involvement or a sequel of eosinophilic pleuritis.
Eosinophilic inﬁ   ltration of the lung is common and 
may be detected as a patchy and migratory inﬁ  ltrate on 
plain X-ray (Figure 4). Bronchoalveolar lavage is per-
formed in order to prove eosinophilic alveolitis, and 
tissue inﬁ  ltration may be seen in trans-bronchial lung 
biopsies. Other forms of alveolitis and mixed patterns 
(neutrophilic and lymphocytic alveolitis) also occur [39]. 
DAH as the clinical equivalent of lung capillaritis can 
occur but is less frequent than in WG and MPA [30] 
(Figure 2).
Diagnostic procedure and therapy and outcome of 
AAV
Diagnostic work-up
AAV patients should undergo a standardized multi-
disciplinary evaluation in order to determine disease 
stage and activity. It is recommended to treat AAV 
patients at or in cooperation with specialist centers [11]. 
All AAV patients require a work-up that includes exami-
nation of lung (X-ray, lung function testing and HRCT, 
and ﬁ  beroptic bronchoscopy with broncho  alveolar lavage 
if necessary) and kidneys (ultrasound, assess  ment of 
creatinine clearance and microscopic hematuria, red cell 
casts and proteinuria) and testing for ANCAs. In 
addition, WG patients should be seen by an otorhino-
laryngologist and CSS patients require assess  ment of 
pulmonary function and allergy testing. At ﬁ  rst 
presentation, conﬁ  rmation of diagnosis should be sought 
by biopsy - for example, nasal mucosa and lung or kidney 
biopsy. Depending on disease symptoms and suspected 
organ manifestations, additional evaluations by a 
neurologist, ophthalmologist and dermatologist and/or 
additional technical examinations, such as MRI of sinuses 
and orbits, may be required.
Patients should be seen and evaluated in regular 
intervals (three- to six-monthly) to assess disease activity 
and adapt immunosuppressive therapy. Ideally, patients 
are evaluated by standardized and validated tools to 
assess disease activity and damage (such as the Birming-
ham Vasculitis Activity Score or the Vasculitis Damage 
Index) [40,41].
Treatment and outcome of Wegener’s granulomatosis and 
microscopic polyangiitis
Treatment follows a stage- and disease activity-adapted 
regimen due to evidence from controlled trials [11]. For 
remission induction in WG and MPA, methorexate 
(MTX) should be used in non-organ-threatening early 
systemic disease and cyclophosphamide in generalized 
disease in addition to glucocorticoids [42,43]. Rituximab 
may be an alternative for cyclophosphamide in the future 
[44,45], even if not yet listed in the treatment recom-
mendations as data have been published only very 
recently. For severe disease, namely acute renal failure, 
additional plasma exchange is recommended [46]. After 
successful remission induction (of 3 to 6 months), MPA 
and WG patients should be switched to maintenance 
therapy with medium-potent immunosuppression (aza-
thio  prin, MTX or leﬂ   unomide) [47-49]. It is recom-
mended that the glucocorticoid dose should not exceed 
10 mg prednisone/day during maintenance. It is not yet 
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this is being investigated in current trials.
Treatment of localized WG and refractory disease 
represent the current challenges in the treatment of AAV. 
For localized disease, no controlled trials are available to 
support therapy decisions. Trimethoprim/sulfomethoxa-
zole may be used for remission induction in upper airway 
disease in WG [50,51] although it was not suﬃ   cient to 
control disease activity in a signiﬁ   cant proportion of 
patients with persistent localized WG [13]. In clinical 
practice, patients in the localized disease stage are treated 
according to disease activity and severity: manifestations 
such as granulomatous sinusitis or subglottic stenosis 
may be treated with MTX. In the case of disease 
progression (that is, granulomatous sinusitis perforating 
the orbital wall and aﬀ  ecting the optic nerve) patients 
usually receive highly potent immuno  suppression.
In spite of the use of highly potent and potentially toxic 
immunosuppression, such as cyclophosphamide, around 
15 to 20% of patients (localized and generalized) do not 
respond to therapy (‘refractory disease’) [4,13]. In this 
situation, rituximab, inﬂ  iximab,  deoxyspergualin, 
antithymocyte globulin, mycophenolate mofetil or intra-
venous immunoglobulins are recommended [11], 
although controlled trials to support these recom  men-
dations are still lacking.
Older age, kidney involvement with impaired renal 
function, pulmonary manifestations at diagnosis and 
absence of ENT symptoms have been related to an 
adverse outcome and increased mortality [4,52,53]. 
Whereas several studies published in the 1990s showed 
an increased mortality of WG and MPA compared to the 
general population [54-57], a decrease in the standardized 
mortality ratios was reported in Swedish patients 
diagnosed before and after 1996 [58]; furthermore, a 
recent study reported no (more) increased mortality rates 
in WG patients diagnosed in the 1990s [59]. Th  e  evidence 
from controlled trials and the implementation of stage- 
and disease activity-adapted regimens have particularly 
contributed to the improved outcome. Regardless, 
mortality rates during the ﬁ   rst year after diagnoses 
remain excessively high (50%), especially in those patients 
who are severely diseased (in the generalized or severe 
disease stage) and treated with highly potent immuno-
suppression [60]. Interestingly, patients died rather from 
infections than from acute vasculitis [60].
Treatment and outcome of Churg-Strauss syndrome
In general, principles of treatment for CSS are the same 
as for the other AAVs. A stage- and disease activity-
adapted approach is recommended. To guide therapy, the 
FFS as an additional instrument should be used [34]. 
Glucocorticoids (GCs) represent the mainstay of CSS 
treatment. In most cases relatively high doses have to be 
used for longer periods of time. As evidence accumulates 
that GCs are also the most signiﬁ   cant risk factor for 
severe infections (see below) and long-term use is asso-
ciated with a high burden of co-morbidity, therapy should 
Figure 4. Diff  use, shadowy infi  ltrate in a patient with Churg-Strauss syndrome (on the left), promptly resolving under glucocortocoid 
therapy within 7 days (on the right).
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treatment with high-dose inhaled corticosteroids may 
help to control asthma in CSS and lower systemic GC 
doses, although prospective data in this respect are not 
available. Medium-potent immunosuppressants, such as 
MTX or azathioprine, may be used for steroid sparing. In 
non-life- or organ-threatening CSS, for example, MTX 
might be used for induction of remission but subsequent 
relapse rates are high [61]. A FFS of ≥1 usually triggers 
intense immunosuppression with cyclophosphamide 
[35]. Further indications for the use of cyclophosphamide 
are severe peripheral nerve involvement or failure of 
medium-potent drugs to control disease activity. Most 
experts recommend maintenance therapy after attaining 
remission for years, although proof of this concept is 
lacking in CSS.
Despite treatment with GCs and cyclophosphamide, 
about 10% of patients show refractory disease courses. 
Th  e reported 5-year mortality rates in recent series are 
about 80% [62]. Several salvage therapies have been 
reported in case reports or small case series. Interferon-α 
is capable of inducing remission but long-term results are 
disappointing [63,64]. Rituximab, as in WG and MPA, 
may be a promising approach but data from larger series 
are still lacking [65]. Some eﬃ   ciency was reported with 
tumor necrosis factor-α blocking agents [66].
A recently published case series reported the steroid 
sparing potential of mepolizumab, an IL-5 antibody, but 
failure to induce remission [67]. In another trial the 
steroid sparing potential was conﬁ  rmed and the capa-
bility of mepolizumab to induce remission in refractory 
and relapsing CSS was shown [68]. Targeting IL-5 
therefore represents the ﬁ  rst targeted approach in CSS 
and warrants further investigations.
Pulmonary manifestations of other vasculitides
Among the small vessel vasculitides, Goodpasture’s syn-
drome (GPS) is responsible for around 20% of alveolar 
hemorrhage due to pulmonary capillaritis. GPS is 
associated with antiglomerular basement membrane 
antibodies (ABMAs), and is rarely conﬁ  ned to the lungs 
but occurs usually in conjunction with glonerulonephritis 
(pulmonary-renal syndrome). ABMAs target type IV 
collagen in basement membranes of lungs and kidneys, 
which may become exposed and thereby accessible for 
ABMAs in the presence of inhalative noxae such as 
cigarette smoke or respiratory infections. GPS typically 
aﬀ   ects young adults (predominantly males) and older 
adults. In around 30% of patients, not only ABMAs but 
also P-ANCAs, usually directed against MPO, are 
present. Th  e mainstay of therapy consists of GCs and 
cyclo  phosphamide. Furthermore, plasmapheresis should 
be performed in patients with pulmonary-renal syn-
drome and in patients with isolated glomerulonephritis 
when there is a chance for renal recovery (reviewed in 
[69]).
Rarely, DAH may occur as a manifestation of Henoch-
Schönlein purpura (HSP) and cryoglubulinemic vasculitis 
(CV), both of which are small vessel immune complex 
vasculitides. HSP (incidence 20 people per 100,000 per 
year) is characterized by immune deposits including IgA. 
It usually aﬀ   ects young children, with a male pre-
dominance. Th  e classic triad of HSP is purpura (due to 
leucocytoclastic vasculitis of small skin vessels), arthritis 
and abdominal pain (due to gastro  intenstinal vasculitis). 
Deposition of immune complexes to the alveolar base-
ment membrane may lead to immune complex pneumo-
nitis and leucocytoclastic capillaritis with subsequent 
DAH. Corticosteroids reduce duration and severity of 
joint and abdominal pain but do not prevent the develop-
ment of nephritis. A wide range of immunosuppressants 
has been used to control disease activity, such as 
azathioprine, mycophenolate, cyclo  sporine and cyclo-
phos  phamide, yet there is currently not enough data 
available from controlled trials to indicate that any of 
these treatments are of deﬁ  nite beneﬁ  t. Regarding cyclo-
phosphamide, a recent study has shown that the combi-
nation of cyclophosphamide and GCs is not superior to 
GC treatment alone. Controlled trials are needed to 
guide treatment strategies in HSP (reviewed in [70]).
Around 2% of patients with CV present with DAH. CV 
may occur as primary ‘essential’ vasculitis or - and much 
more frequently - as secondary vasculitis, mostly due to 
infection with the hepatitis C virus. Typical CV 
manifestations are purpura, arthritis, polyneuropathy 
and glomerulonephritis (membranoproliferative glomeru-
lo  nephritis type 1) [71]. In essential CV, GC treatment in 
conjunction with medium- to highly potent immuno-
suppression is recommended [11]. For hepatitis C virus-
associated CV, anti-viral therapy is indicated. Rituximab 
may also be of beneﬁ  t in the treatment of CV [11].
Small vessel vasculitis with lung involvement and 
consecutive alveolar hemorrhage may also develop rarely 
in collagen vascular diseases (such as systemic lupus 
erythematosus and systemic sclerosis).
Panrarteritis nodosa (PAN) is a systemic necrotizing 
vasculitis that predominantly aﬀ  ects  medium-size 
arteries and may lead to stenosis or formation of micro-
aneurysms, which can rupture and cause major bleeding. 
PAN is primary in the majority of patients but may also 
occur in association with viral infections, especially with 
hepatitis B virus. Apart from constitutional symptoms, 
peripheral neuropathy, skin involvement (livedo, purpura, 
digital ischemia), gastrointestinal involvement with 
bleed  ing and perforation, renal artery stenosis and hyper-
tension are common [72]. Pulmonary involvement (lung 
inﬁ   ltrates, pleural eﬀ   usions) is rare (in around 4% of 
patients [72]). For hepatitis B-related PAN, the use of 
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exchange also seems successful in remission induction 
[73]. Non-infectious PAN is treated by GCs in conjunc-
tion with medium- to highly potent immunosuppressants.
Large vessel involvement of the lungs is found in two 
conditions, Takayasu arteritis and Behcet’s disease (BD). 
Takayasu arteritis is a large vessel vasculitis mainly 
aﬀ   ecting young females in Japan and Southeast Asia. 
Most frequently, subclavian and carotid arteries are 
involved followed by adominal aorta and mesentery 
arteries. Brachiocephalic involvement may also occur, 
usually in conjunction with Takayasu arteritis inﬂ  amma-
tion at other sites. Isolated pulmonary artery involvement 
is rare [74]. Stenosis and occlusion is the typical compli-
cation, but dilatation and aneurysms may also be found. 
Patients should receive GCs and an adjunctive immuno-
suppressive agent, such as azathioprine, MTX or 
cyclophosphamide, for remission induction [73]. Recon-
structive surgery should be performed when the patient 
is in remission if possible [73]. BD is a rare multisystemic 
and chronic inﬂ   ammatory disorder that is associated 
with recurrent oral and genital ulcers, eye involvement 
(uveitis) and skin lesions (for example, erythema 
nodosum). It is most commonly found in young males 
and occurs most frequently in countries along the old silk 
route. Th   ere is a strong association with HLA-B51 in BD 
patients. Th   e most common vascular involvement of BD 
is venous thrombophlebitis. Pulmonary artery vasculitis 
is present in 5% of cases and may lead to arterial and 
venous occlusion/thrombosis, aneurysms, infarction, 
hemorrhage and arteriovenous shunts. BD is the most 
common cause of pulmonary artery aneurysms (reviewed 
in [75]). If untreated, the mortality rate of BD patients 
with pulmonary artery aneurysms is 30% within 2 years. 
Treatment for BD consists of GCs plus adjunctive con-
ventional immuno  suppressants depending on disease 
mani  festation and activity [76]. GCs plus cyclophos-
phamide may be eﬀ  ective in the treatment of aneurysmal 
dilatation.
Importantly, thromboembolisms may occur not only in 
BD but also in other vasculitides, especially in AAV [77]. 
A recent study showed that around 12% of AAV patients 
develop thromboembolism, usually during active disease 
[77].
Vasculitis related to drugs and occupational exposure
Drugs such as propylthiouracil, gemcitabine, trans-
retinoic acid and cocaine may also cause pulmonary 
capillaritis and DAH and are often associated with the 
presence of ANCAs [78]. Moreover, certain occupational 
exposures, such as to silica from speciﬁ  c farming tasks 
related to harvesting, have been suggested to be 
associated with AAV in case-control studies [79], but the 
data are controversial [80].
Pulmonary infections as a comorbidity in 
vasculitides
Risk of infection under immunosuppressive therapy
Infections in AAVs may be related to immunosuppressive 
therapy or the severity of the disease or both [81] and 
have been reported to occur in 6 to 55% of AAV patients 
[82,83]. In particular, high doses of GCs (often deﬁ  ned as 
30 mg prednisolone/day) and cyclophosphamide have 
been shown to be associated with infections in AAVs 
[84]. Th   e dose of oral cyclophosphamide at the time point 
of infection as well as the cumulative oral cyclo-
phosphamide dose were identiﬁ  ed as risk factors [84]. 
Moreover, the rate of infections within the ﬁ  rst 3 years of 
follow-up was related to the cumulative doses of 
cyclophosphamide and GCs [84]. Biologics are 
increasingly used for remission induction in AAV, with 
similar risk of infection compared to conventional 
therapy: in a randomized controlled trial of oral cyclo-
phos  phamide versus rituximab, the rates of infections in 
both arms were similar (around 7% of subjects had 
infections of grade 3 or higher) [44].
In refractory AAV, even more intensive therapy may be 
administered, as biologics are often used in conjunction 
with medium- or highly potent immunosuppression. 
Serious infections were reported in 20% of refractory 
AAV patients treated with rituximab plus additional 
medium- or highly potent conventional immunosup-
pression, most of whom had pneumonias (14%) [85]. 
Under anti-thymocyte globulin or deoxyspergualin in 
combination with GCs, even 40% and 78% of patients, 
respectively, suﬀ  ered from infections [86,87].
Time point and kind of infection during the course of 
disease
A study on risk factors for major infection in WG found 
that half of the major infections occurred within 3 years 
after WG diagnosis [84]. Furthermore, infections and not 
active vasculitis represent the main cause of ‘early 
mortality’ (mortality within the ﬁ  rst year of diagnosis) in 
AAVs. ‘Early mortality’ was higher in study populations 
with more severe disease (in the generalized or severe 
stage of the disease) who received more intensive 
immunosuppression (cyclophosphamide or cyclophos-
phamide plus plasma exchange) [60]. In summary, 
patients seem to be most vulnerable to infections shortly 
after diagnosis. Whether this relates to the intensive 
immunosuppression required for remission induction or 
whether the disease and disease activity itself also 
accounts for a suppression of the immune system and an 
increased risk of death has not been determined.
Most of the controlled trials in AAV give the rate of 
infection, but do not specify the kind of infection [42,43]. 
Yet, a large retrospective study on WG patients and 
major risk factors for infections reported that pneumonia 
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under immunosuppression in AAVs [84]. Pneumonia 
accounted for 36% of all major infections, followed by 
viral infections (17%). Likewise, lower respiratory tract 
infection has been reported as the most frequent infec-
tion in refractory AAV patients treated with rituximab 
and deoxyspergualin [86,87]. An intensiﬁ  ed  diagnostic 
approach including bronchoscopy with bronchoalveolar 
lavage is recommended in immunosuppressed patients 
with pneumonia because of the broad spectrum of 
pathogens and the uncertainties of empirical anti  micro-
bial coverage in this population.
Pneumocystis jirovecii pneumonia (PJP) is a dreaded 
complication of immunosuppression and has been shown 
to occur most frequently in patients undergoing intense 
remission induction therapy [88]. Furthermore, among 
AAV patients, those with WG seem particularly at risk of 
developing PJP [81]. Without the use of PJP prophylaxis, 
the incidence of PJP was reported to be up to 20% [82]. 
Age, as well as a low lymphocyte count before and during 
therapy and prolonged GC doses of >15 to 20 mg/day, are 
risk factors for PJP [88-91]. Although there are no 
controlled data on PJP prophylaxis in AAV, it is 
recommended as infection rates were much higher in 
trials not using prophylaxis compared to trials encourag-
ing it [82,92]. Mahr and colleagues [93] reported no more 
occurrence of PJP since the introduction of PJP 
prophylaxis. PJP prophylaxis with trimethoprim/sulfo-
methoxa  zole is encouraged by European guidelines in all 
patients receiving cyclophosphamide [11].
Conclusion
Th   e AAVs share the features of small vessel vasculitis and 
a (variable) association with ANCAs. Pulmonary 
capillaritis is the classic manifestation of small vessel 
vasculitis, occurring in all of the three AAVs. In WG the 
spectrum of the disease also encompasses mass forma-
tion (‘granulomatous disease’), which is most prevalent in 
the upper and lower respiratory tracts (that is, pulmonary 
granuloma). In CSS, ‘granuloma formation’ may also be 
found, though less pronounced; furthermore, asthma and 
eosinophilic organ inﬁ   ltration, such as eosinophilic 
alveolitis, are hallmarks of CSS. GCs and cyclophos-
phamide are the mainstay of remission induction in 
generalized disease (such as pulmonary capillaritis), and 
there is good evidence for the use of maintenance therapy 
(MTX, azathioprine or leﬂ  unomide) in conjunction with 
GCs in WG and MPA. Rarely, other vasculitides are 
associated with pulmonary manifestations: DAH may 
also occur in GPS, HSP, CV and collagen vascular 
diseases. Pulmonary artery occlusion due to thrombosis 
and pulmonary artery aneurysms are a feared compli-
cation in BD. Infections, particularly those aﬀ  ecting the 
lower respiratory tract, remain a major problem under 
intense immunosuppression, including biologics. Yet, it is 
suggested that PJP prophylaxis is eﬀ   ective in patients 
receiving cyclophosphamide.
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